Cerebrolysin for Concussion Recovery: The Trial Data

Peptides for TBI Recovery

CAPTAIN trial series

The largest clinical trial program studying cerebrolysin in traumatic brain injury, showing statistically significant improvements in functional outcomes at 30 and 90 days.

Vester et al., Neurological Sciences, 2021

Vester et al., Neurological Sciences, 2021

View as image

Cerebrolysin is a porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids. Manufactured by EVER Pharma (Austria), it has been used in clinical practice across Europe, Asia, and Latin America for decades, primarily for stroke, Alzheimer's disease, and traumatic brain injury. It is not FDA-approved in the United States. For context on the broader peptide landscape in brain injury treatment, see our overview of peptides for TBI recovery.

The clinical evidence for cerebrolysin in concussion and traumatic brain injury has accumulated through a series of trials, culminating in the CAPTAIN (Cerebrolysin And Recovery After Acute Brain Injury: Analysis of a Multicenter, Randomized, Double-blind, Placebo-controlled Trial) program. This article examines what the trials show, what they don't, and where the evidence stands relative to the claims made about this peptide preparation.

What Cerebrolysin Contains

Unlike synthetic peptide drugs with a single defined sequence, cerebrolysin is a mixture. It contains approximately 25% low-molecular-weight peptides and 75% free amino acids, derived from porcine brain tissue through a standardized enzymatic degradation process. The peptide fraction includes fragments that mimic the activity of endogenous neurotrophic factors including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).^[1]

This composition means cerebrolysin acts through multiple simultaneous mechanisms rather than a single receptor-ligand interaction. The neurotrophic peptide fragments promote neuronal survival, axonal sprouting, and synaptic plasticity. Studies on PC12 cells (a standard neuronal cell culture model) demonstrated that cerebrolysin protected against various neurotoxic insults, including oxidative stress, glutamate excitotoxicity, and serum deprivation.^[2] These protective effects resemble what BDNF does naturally in the brain.

The multi-component nature of cerebrolysin is both its strength and its regulatory challenge. The mixture may provide broader neuroprotection than any single peptide, but it also makes the drug harder to characterize by modern pharmaceutical standards that prefer defined molecular entities.

The Mild TBI Evidence

The most directly relevant study for concussion recovery is a 2013 double-blind, placebo-controlled, randomized trial conducted in Taiwan. Chen and colleagues enrolled 32 patients with mild traumatic brain injury (Glasgow Coma Scale 13-15) and randomized them to receive either cerebrolysin (30 mL/day intravenously for 5 days) or placebo. The primary outcomes were cognitive function assessments at 1 and 3 months post-injury.

Patients receiving cerebrolysin showed statistically significant improvements in overall cognitive function measured by the Cognitive Abilities Screening Instrument (CASI), with particular improvements in drawing function and long-term memory compared to the placebo group at 3 months. The effect was clinically relevant: the cerebrolysin group showed faster resolution of post-concussive cognitive symptoms.

The study has clear limitations. The sample size (32 patients) is small. The trial was conducted at a single center. The 5-day treatment window is brief, and longer-term follow-up was not reported. Intravenous administration over 5 days is practical for hospitalized patients but impractical for the majority of concussion patients who are managed as outpatients. Despite these limitations, this remains the only published placebo-controlled RCT of cerebrolysin specifically in mild TBI.

The CAPTAIN Trial Series

The largest body of evidence for cerebrolysin in TBI comes from the CAPTAIN program, which studied moderate to severe cases (not mild concussion).

CAPTAIN I was a multicenter, randomized, double-blind, placebo-controlled trial in moderate-to-severe TBI patients. Participants received cerebrolysin (50 mL/day) or placebo for 10 days, with outcomes assessed using the Glasgow Outcome Scale-Extended (GOSE) at 90 days.

CAPTAIN II (Muresanu et al., Neurological Sciences, 2020) expanded the program with a similar design, enrolling additional patients across multiple centers. The trial confirmed cerebrolysin's safety and showed improvements in functional outcomes, with particularly notable effects on anxiety and depression scores in the moderate TBI subgroup (Muresanu et al., CNS & Neurological Disorders Drug Targets, 2022).

A prospective meta-analysis combining data from the CAPTAIN trials found a "small-to-medium" effect size favoring cerebrolysin over placebo on the GOSE at both 30 and 90 days (Vester et al., Neurological Sciences, 2021). The effect was statistically significant, indicating that cerebrolysin produced measurable improvements in functional recovery after moderate-severe TBI. A cost-effectiveness analysis based on these data found cerebrolysin had a high probability of being cost-effective in moderate TBI patients.

Mechanism: How Cerebrolysin May Help After Brain Injury

The rationale for using cerebrolysin after traumatic brain injury rests on its neurotrophic and neuroprotective properties, which address several pathological processes that occur after concussion.

Oxidative stress reduction. A 2012 study demonstrated that cerebrolysin administration reduced markers of oxidative stress in neuronal cell models, decreasing reactive oxygen species production and lipid peroxidation. This is relevant because oxidative damage is a major secondary injury mechanism after TBI, peaking in the hours to days after the initial impact.^[3]

Neurotrophic factor modulation. Cerebrolysin contains peptide fragments that activate the same signaling pathways as endogenous neurotrophic factors. A 2023 study on neurotrophic factor modulation demonstrated that exogenous neurotrophic signaling can enhance synaptic plasticity and neuronal survival after injury, providing a mechanistic basis for cerebrolysin's cognitive benefits.^[4]

Anti-inflammatory effects. Cerebrolysin has been shown to reduce neuroinflammation in animal models of brain injury. The inflammatory cascade after TBI involves microglial activation, cytokine release, and blood-brain barrier disruption, all of which contribute to secondary damage. Reducing this inflammatory response within the therapeutic window may limit the extent of secondary injury. A broader review of neuroprotective peptides confirmed that multi-target peptide preparations may be particularly suited to the complex pathophysiology of TBI, which involves simultaneous oxidative, inflammatory, and excitotoxic damage.^[5]

Synaptic plasticity enhancement. Studies on cerebrolysin's effects on synaptic function suggest it promotes long-term potentiation and dendritic branching, processes essential for learning and memory recovery after brain injury.^[6] Animal models of TBI treated with cerebrolysin showed dose-dependent improvements in spatial memory and motor function (Zhang et al., Journal of Neurotrauma, 2018). This is relevant to the broader question of how neuroprotective peptides work within the therapeutic window after injury.

The Retrospective and Observational Data

Beyond the controlled trials, several observational studies provide additional data on cerebrolysin in TBI.

A multi-center retrospective cohort study of 7,784 TBI patients across severity levels (Muresanu et al., 2015) found that cerebrolysin-treated patients had higher rates of favorable outcomes at day 21. The effect was severity-dependent: patients with mild TBI showed improvements at 10 days, while moderate and severe TBI patients showed improvements at 10 and 30 days. The retrospective design limits causal inference, but the large sample size and consistent direction of effect add weight to the prospective trial findings.

A separate study found a significantly shorter mean length of hospital stay (approximately 7 days shorter) in severe TBI patients receiving cerebrolysin compared to controls, which has both clinical and economic implications.

The observational data consistently favors cerebrolysin, but observational studies are susceptible to confounding: physicians may be more likely to prescribe cerebrolysin to patients they judge more likely to recover, or treatment selection may differ systematically between centers. The larger context is that cerebrolysin is one of the few neuroprotective agents to show consistent positive signals across both randomized and observational TBI studies, a distinction that most neuroprotective drug candidates have failed to achieve.^[8] Cerebrolysin's clinical track record in related indications, including vascular dementia, further supports the biological plausibility of neurotrophic peptide therapy for injured brain tissue.^[9][10]

Limitations and Open Questions

The cerebrolysin TBI evidence has several limitations that are important to acknowledge.

Small RCT evidence for mild TBI. The only placebo-controlled RCT in mild TBI enrolled 32 patients. For a condition as common as concussion (estimated 3.8 million per year in the United States alone), this evidence base is thin. Larger multi-center RCTs focused specifically on concussion recovery are needed before strong conclusions can be drawn for this population.

Route of administration. Cerebrolysin is given intravenously, which limits its utility for outpatient concussion management. Most concussion patients are seen in emergency departments and discharged home. A treatment requiring multi-day IV infusions does not fit this clinical workflow unless efficacy is sufficient to justify admission or outpatient infusion center visits.

Undefined molecular composition. The exact peptide sequences in cerebrolysin are not fully characterized. This makes it difficult to determine which components are responsible for the observed effects and complicates efforts to optimize the formulation or develop defined synthetic alternatives. Cortexin, another brain-derived peptide preparation, shares this characterization challenge.

Geographic and regulatory variation. Most cerebrolysin trials were conducted in Europe, Asia, and Latin America. The drug lacks FDA approval in the United States, and the trial designs may not meet FDA evidentiary standards for approval. Interpretation of results should account for potential differences in standard-of-care treatment between trial sites and U.S. practice. The standard of care for TBI management, particularly regarding ICP monitoring, early rehabilitation, and neurosurgical intervention timing, varies between U.S. academic medical centers and hospitals in other parts of the world. An effect that is additive to one standard of care may be redundant or insufficient in another.

Comparison to other peptide approaches. How cerebrolysin compares to other peptide-based approaches for brain injury recovery, including BPC-157 in TBI animal models or neurotrophic factor supplementation, remains unclear. No head-to-head comparative trials exist. Cerebrolysin's advantage over single-target peptides is its multi-mechanism approach; its disadvantage is that no one can precisely identify which peptide fragments are doing the work. The neurotrophic peptide field would benefit from defined-sequence alternatives that replicate cerebrolysin's multi-target profile while meeting modern pharmaceutical characterization standards.^[7]

Timing of treatment. The therapeutic window for cerebrolysin after TBI has not been precisely defined. Most trials began treatment within 24 hours of injury. Whether starting cerebrolysin 48 or 72 hours after a concussion would produce similar benefits is unknown. Given that secondary injury cascades (inflammation, oxidative stress, excitotoxicity) evolve over the first week after TBI, there may be a meaningful window for late intervention, but this has not been tested in controlled settings. The broader question of neuroprotective peptide timing after brain injury applies directly to cerebrolysin.

The Bottom Line

Cerebrolysin has the most clinical trial data of any peptide preparation for traumatic brain injury. The CAPTAIN trial series provides statistically significant evidence for moderate-severe TBI, and a small RCT supports cognitive recovery benefits in mild TBI. The drug's multi-target mechanism (neurotrophic, antioxidant, anti-inflammatory) is well-matched to TBI's complex pathophysiology. The primary limitations are the small sample size for mild TBI specifically, the IV-only route of administration, and lack of FDA approval. For concussion patients specifically, the evidence is suggestive but insufficient for definitive clinical recommendations, and larger trials in mild TBI populations are the critical next step.

Frequently Asked Questions

Does cerebrolysin help with concussion recovery?

A small placebo-controlled trial (32 patients) found cerebrolysin improved cognitive function, drawing ability, and long-term memory in mild TBI patients at 3 months compared to placebo. The CAPTAIN trial series provides additional evidence for moderate-severe TBI. The evidence is promising but limited for mild concussion specifically, primarily due to small sample sizes.

Is cerebrolysin FDA approved for brain injury?

No. Cerebrolysin is not FDA-approved in the United States for any indication. It is approved and used in over 45 countries across Europe, Asia, and Latin America for traumatic brain injury, stroke, and Alzheimer's disease. Regulatory standards vary by country, and most clinical trials were conducted outside the United States.

What are the side effects of cerebrolysin?

Across clinical trials in TBI, cerebrolysin had a safety profile similar to placebo. The most commonly reported adverse events include dizziness, headache, and injection site reactions. The CAPTAIN trial series reported no serious safety signals. As with any intravenous medication, there is a theoretical risk of allergic reaction, particularly since cerebrolysin is derived from porcine brain tissue.

How is cerebrolysin administered for TBI?

Cerebrolysin is given by intravenous infusion, typically 30-50 mL/day diluted in saline, administered over 15-60 minutes. In the mild TBI trial, treatment lasted 5 days. In the CAPTAIN trials for moderate-severe TBI, treatment lasted 10 days. There is no oral formulation, which limits its use in outpatient concussion management.

What is in cerebrolysin?

Cerebrolysin is a standardized mixture of approximately 25% low-molecular-weight peptides and 75% free amino acids derived from porcine brain tissue. The peptide fraction contains fragments that mimic the activity of neurotrophic factors including BDNF, NGF, and CNTF. Unlike most modern drugs, it is a complex biological mixture rather than a single defined molecule.

How does cerebrolysin compare to BPC-157 for brain injury?

The two peptides have fundamentally different evidence profiles. Cerebrolysin has multiple human clinical trials in TBI, including a placebo-controlled RCT and the CAPTAIN trial series. BPC-157 has only animal model data for brain injury. Cerebrolysin is an approved drug in many countries; BPC-157 is not approved anywhere for any indication. No head-to-head comparison exists.